Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023
New Jersey United States Hemophagocytic Lymphohistiocytosis Ying Huang Drug Administration European Commission
Source: marketscreener.com